A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Preparing for the 2024 ‘tripledemic’
Now is the time to arm Australians with vaccines, respiratory disease advice, testing and essential medicines to get ahead of respiratory ailment season.
The trifecta...
Exenatide for alcohol use disorder
A better understanding of exenatide can help increase our knowledge of GLP-1 analogues and their possible role in treating addiction.
A good night’s sleep
References
1. Hillman D, Mitchell S, Streatfeild J, et al. The economic cost of inadequate sleep. Sleep 2018;41(8). Epub 2018 Jun 4.
2. Claughton D. Farmers...
Oral Antihyperglycaemics for COPD exacerbations
Emerging evidence is pointing to the benefits of ‘novel’ antihyperglycaemics on lung function in COPD patients.
Waiting to inhale
Annoyed by her glass squeeze-bulb nebuliser, 13-year old asthmatic Susie Maison asked "Daddy why can't they put my asthma medicine in a spray can?"
